Histology and oncogenic driver alterations of lung adenocarcinoma in Chinese

被引:1
|
作者
Shang, Guoguo [1 ,2 ,3 ]
Jin, Yan [1 ,2 ]
Zheng, Qiang [1 ,2 ]
Shen, Xuxia [1 ,2 ]
Yang, Mu [4 ]
Li, Yuan [1 ,2 ]
Zhang, Lanjing [5 ,6 ,7 ,8 ]
机构
[1] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai 200032, Peoples R China
[2] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China
[3] Fudan Univ, Dept Pathol, Zhongshan Hosp, Shanghai, Peoples R China
[4] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Pathol, Sch Med, Shanghai, Peoples R China
[5] Rutgers State Univ, Dept Biol Sci, Newark, NJ USA
[6] Med Ctr Princeton, Dept Pathol, Plainsboro, NJ USA
[7] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[8] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Chem Biol, Piscataway, NJ USA
来源
AMERICAN JOURNAL OF CANCER RESEARCH | 2019年 / 9卷 / 06期
基金
中国国家自然科学基金;
关键词
Lung cancer; pathology; survival; oncogenic driver; adenocarcinoma; INVASIVE MUCINOUS ADENOCARCINOMA; CLINICOPATHOLOGICAL CHARACTERISTICS; INTERNATIONAL ASSOCIATION; FUSIONS DEFINE; RET FUSIONS; ALK; MUTATIONS; PROGNOSIS; SUBTYPES; SMOKERS;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Little is known about association of mucin abundancy with oncogenic-driver alterations, immunohistochemical and clinicopathologic features in lung adenocarcinomas among Chinese. We here retrospectively examined the clinicopathologic and molecular characteristics of pulmonary mucin-producing adenocarcinoma (PMPA) and previously-reported non-mucinous lung adenocarcinomas collected at our institution. Among the 897 non-mucinous adenocarcinomas, 61 PMPA with <= 90% mucin and 39 PMPA with >90% mucin, ALK rearrangements were found in 47 (5.2%) non-mucinous adenocarcinomas, 9 (14.8%) PMPA with 5.90% mucin and 12 (30.8%) PMPA with >90% mucin, respectively, with an ordinal association (coefficient, 95% CI=0.11, 0.06 to 0.17). Similarly, KRAS mutations was found in 53 (5.9%) non-mucinous adenocarcinomas, 7 (11.5%) PMPA with <= 90% mucin and 14 (35.9%) PMPA with >90% mucin (coefficient, 95% CI=0.11, 0.05 to 0.16). However, mucinous abundancy was inversely, ordinally linked to the EGFR mutations (coefficient, 95% C1=-0.28, -0.33 to -0.22). Mucin abundancy seemed not associated with the alterations of HER2, BRAF, ROS1, MET and RET. We divided PMPA with >90% mucin into three histologic types, namely columnar mucinous cell with basal nuclei (type I, n=11), cuboidal cell with goblet cell feature (type II, n=16) and mucinous cribriform pattern (type III, n=12). These histologic subtypes were associated with alterations of ALK, KRAS and MET, and the immunohistochemical reactivity of MUC1, MUC2, MUC5ac, MUC6, TTF-1 and CK20, including high positive rate of MUC6 (90.9%) and CK20 (36.4%) in type I, MUC2 (50%) in type II and MUC1 (100%) in type III. In summary, mucin abundancy is associated with immunohistochemical and oncogenic-driver profiles of lung adenocarcinomas among Chinese.
引用
收藏
页码:1212 / 1223
页数:12
相关论文
共 50 条
  • [21] ONCOGENIC DRIVER MUTATIONS IN CHINESE NON-SMALL CELL LUNG CANCER (NSCLC)
    He, J.
    Yang, H.
    Deng, Q.
    He, P.
    Jiang, J.
    Zhao, M.
    Gu, X.
    Zheng, L.
    Pang, H.
    Zhou, J. X.
    ANNALS OF ONCOLOGY, 2012, 23 : 389 - 390
  • [22] CLINICAL CHARACTERISTICS AND PROGNOSIS OF LUNG ADENOCARCINOMA DRIVER MUTATIONS FROM CHINESE POPULATION
    Dong, Yu
    Li, Ying
    Jin, Bo
    Peng, Hong
    Xiong, Hui
    Han, Baohui
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S918 - S918
  • [23] ONCOGENIC ARAF MUTATION IN LUNG ADENOCARCINOMA
    Imielinski, Marcin
    Greulich, Heidi
    Kaplan, Bethany
    Araujo, Luiz
    Amann, Joseph
    Horn, Leora
    Villalona-Calero, Miguel
    Meyerson, Matthew
    Carbone, David P.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S349 - S350
  • [24] Oncogenic driver mutations in Swiss never smoker patients with lung adenocarcinoma and correlation with clinicopathologic characteristics and outcome
    Grosse, Claudia
    Soltermann, Alex
    Rechsteiner, Markus
    Grosse, Alexandra
    PLOS ONE, 2019, 14 (08):
  • [25] Sputum cell-free DNA for detection of alterations of multiple driver genes in lung adenocarcinoma
    Wang, Zheng
    Li, Lin
    Wang, Yifei
    Li, Xiaoguang
    Xu, Yan
    Wang, Mengzhao
    Liang, Li
    Wu, Xiaonan
    Tang, Min
    Li, Yuanming
    He, Shurong
    Du, Jun
    He, Lei
    Sun, Mingjun
    Yang, Li
    Di, Jing
    Gai, Fei
    Liu, Dongge
    CANCER CYTOPATHOLOGY, 2023, 131 (02) : 110 - 116
  • [26] Genomic alterations in lung adenocarcinoma
    Devarakonda, Siddhartha
    Morgensztern, Daniel
    Govindan, Ramaswamy
    LANCET ONCOLOGY, 2015, 16 (07): : E342 - E351
  • [27] Integrated analysis of genomic alterations of Chinese lung adenocarcinoma with micropapillary component.
    Wang, Yongjie
    Yang, Ronghua
    Wang, Dong
    Zhang, Shanshan
    Xuan, Yunpeng
    Li, Peng
    Wang, Lingjie
    Che, Shuyu
    Han, Minghui
    Yu, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] DRIVER GENE ALTERATIONS IN CHINESE NON-SMALL CELL LUNG CANCER PATIENTS
    Wu, Y.
    An, S.
    Chen, Z.
    Su, J.
    Zhang, X.
    Zhong, W.
    Yang, J.
    Zhou, Q.
    Yang, X.
    Mok, T.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S30 - S30
  • [29] Oncogenic Alterations in Histologically Negative Lymph Nodes Are Associated with Prognosis of Patients with Stage I Lung Adenocarcinoma
    Tian, Yiping
    Lai, Qian
    Zheng, Yuansi
    Ying, Lisha
    Wang, Canming
    Jin, Jiaoyue
    Huang, Minran
    Wu, Yingxue
    Li, Huizhang
    Zhang, Jianjun
    Su, Dan
    CANCERS, 2022, 14 (03)
  • [30] Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
    Mazieres, J.
    Drilon, A.
    Lusque, A.
    Mhanna, L.
    Cortot, A. B.
    Mezquita, L.
    Thai, A. A.
    Mascaux, C.
    Couraud, S.
    Veillon, R.
    Van Den Heuvel, M.
    Neal, J.
    Peled, N.
    Fruh, M.
    Ng, T. L.
    Gounant, V
    Popat, S.
    Diebold, J.
    Sabari, J.
    Zhu, V. W.
    Rothschild, S. I.
    Bironzo, P.
    Martinez-Marti, A.
    Curioni-Fontecedro, A.
    Rosell, R.
    Lattuca-Truc, M.
    Wiesweg, M.
    Besse, B.
    Solomon, B.
    Barlesi, F.
    Schouten, R. D.
    Wakelee, H.
    Camidge, D. R.
    Zalcman, G.
    Novello, S.
    Ou, S. I.
    Milia, J.
    Gautschi, O.
    ANNALS OF ONCOLOGY, 2019, 30 (08) : 1321 - 1328